
uniQure reports 4-year data showing slowed Huntington's disease progression with gene therapy AMT-130
uniQure released four-year data from its phase 1/2 trial of AMT-130, a gene therapy for Huntington's Disease. The data showed a 44% slowing in disease progression measured by cUHDRS at year 4, though this result was not statistically significant, pos...





